17
Participants
Start Date
June 25, 2009
Primary Completion Date
July 16, 2013
Study Completion Date
August 20, 2016
RAD001
5 mg/day PO (oral)
erlotinib
100 mg/day (oral)
University of California, San Francisco, San Francisco
Collaborators (2)
Genentech, Inc.
INDUSTRY
Novartis Pharmaceuticals
INDUSTRY
The V Foundation for Cancer Research
OTHER
University of California, San Francisco
OTHER